|
All RT
(n = 340)
A U |
RT till April 2008 RT since April 2008
(n = 197) (n = 143)
Group 1 Group 2 |
p |
|
92 (27) 248(73) |
53 (26.9) |
39 (27.3) |
|
Donor gender
Female
Male |
214 (58)
126 (42) |
124 (63)
73 (37) |
90 (63)
53 (37) |
0.25
0.48 |
Recipient gender
Female
Male |
43 (47) 109(44)
49 (53) 139 (56) |
25 (47.2)
28 (52.8) |
18 (46.2)
21 (53.8) |
0.37
0.36 |
Recipient age at transplantation (years) |
51 (23-70) |
55 (49-69) |
50 (27- 69) |
0.57 |
Donor age (years) |
63 (38-80) |
60 (50- 72) |
58 (22-73) |
0.82 |
Renal disease
Glomerulonephritis
Interstitial nephritis
Polycystic kidney disease
Unspecified |
38 (41) 107 (43)
20 (22) 54 (22)
18 (20) 50(20)
16 (17) 37 (15) |
21 (40)
11 (20)
11 (20)
10 (19) |
16 (41)
9 (23)
8 (20)
6 (15) |
0.38
0.55
0.81
0.38 |
Duration of dialysis
median months (range) |
38 (0-60) |
35 (10- 54) |
36 (3- 60) |
0.59 |
Hemodialysis |
68 (74) 186 (75) |
40 (75) |
28 (72) |
0.79 |
Peritoneal dialysis |
24 (26) 62 (25) |
13 (25) |
11 (28) |
0.48 |
Donor source
Deceased donor
Living donor |
88 (96) 243 (98)
4 (4) 5 (2) |
51 (96)
2 (4) |
37 (95)
2 (3) |
0.44
0.38 |
Treatment AR
Cs
ATG |
46 (50) 26 (10.5) 10 (10.8) 5 (2) |
26 (49)
6 (11) |
20 (45)
4 (10.3) |
0.38
0.36 |
CMV prophylaxis or treatment before diagnosis |
53 (58) 27 (11) |
30 (57) |
23 (54) |
0.73 |
Immunosuppressive therapy
Cya, MMF, Cs (n = 295)
Fk, MMF, Cs (n = 45) |
57 (19) 238 (81)
35 (78) 10 (22) |
33 (62)
20 (38) |
24 (62)
15 (38) |
0.57
0.84 |
